New Delhi: Yatharth Hospital is set to receive a ₹3,150 crore capital infusion from global private equity firm Advent International, marking a significant investment in India’s hospital sector.
With the Competition Commission of India (CCI) clearing the proposed acquisition of a 24.87% stake through Advent’s investment vehicle, Rasmalai Limited, the deal brings fresh attention to the role of private equity capital in expanding India’s organised healthcare infrastructure.
For Advent, the investment represents an opportunity to back a hospital chain with an established presence across North India and plans to expand its network.
For Yatharth Hospital, the proposed capital infusion offers resources to strengthen its hospital footprint, support expansion and build on its recent financial growth.
The transaction is structured as a preferential issue of equity shares and warrants.
Once completed, Rasmalai is expected to hold approximately 24.87% of Yatharth Hospital’s post-issue share capital on a fully diluted basis.
The company has classified the investment as a minority stake, with no change in management control.
The CCI approved the proposed combination at its meeting on 10 November 2026 under Section 31(1) of the Competition Act, 2002.
However, the investment is not yet complete and remains subject to other applicable regulatory and statutory requirements.
Why Yatharth Hospital Attracted a ₹3,150 Crore Investment
The investment comes as Yatharth Hospital continues to expand its presence across North India’s healthcare market.
Founded in 2008, the company operates nine multi-speciality hospitals across the National Capital Region, Agra and Jhansi-Orchha in Madhya Pradesh.
Its network includes hospitals in Noida, Greater Noida, Noida Extension, Greater Faridabad, New Delhi, Faridabad and Gurugram.
Yatharth Hospital has a stated capacity of more than 2,800 beds, including a 250-bed hospital under construction in Gurugram. Its operational census beds stood at 1,820 in the September 2026 quarter.
The upcoming Gurugram facility is expected to commence operations in the first half of FY28, adding to the company’s existing hospital network.
The company’s financial performance also provides context for the investment.
Yatharth Hospital reported consolidated revenue of ₹431.4 crore in the September 2026 quarter, registering 52% year-on-year growth.
EBITDA increased 50% to ₹102 crore, with a margin of 23.6%, while profit after tax rose 17% to ₹48.5 crore.
Hospital occupancy stood at 72%, and average revenue per occupied bed increased 11% year-on-year to ₹35,948.
These figures reflect the operating scale and financial performance of the hospital chain as it prepares for its next phase of expansion.
Advent International’s Healthcare Investment Strategy in India
Yatharth Hospital is not Advent International’s first exposure to India’s healthcare ecosystem.
The global private equity firm has investments across healthcare businesses, including Apollo 24/7, Cohance, Felix Pharma, Bharat Serums and Vaccines, and Care Hospitals.
Its previous transactions include the sale of Bharat Serums and Vaccines to Mankind Pharma for approximately $1.6 billion in 2024. Advent had also agreed to acquire a controlling stake in Suven Pharmaceuticals in 2022.
Founded in 1984, Advent International has made more than 460 investments across 45 countries, according to Yatharth Hospital’s EGM notice.
The notice cited assets under management of approximately $94 billion as of 30 June 2026, while Advent’s September announcement put the figure at more than $109 billion, including advisory-client and co-investment assets.
The proposed ₹3,150 crore investment in Yatharth Hospital adds another hospital-sector exposure to this portfolio.
Advent has described the transaction as one of the largest primary capital infusions by a private equity firm in India’s hospital sector.
What Changes for Yatharth Hospital’s Promoters?
While the investment brings substantial capital into Yatharth Hospital, it also changes the company’s ownership structure.
The Tyagi family’s shareholding is expected to decline from 55.80% to 41.82% on a fully diluted basis after the preferential issue and conversion of all warrants.
Despite the dilution, the promoter family will continue to be the largest shareholder.
Rasmalai will be classified as a public, non-promoter shareholder, and Yatharth Hospital has stated that there will be no change in control.
The proposed investment includes provisions for Advent to nominate up to two non-executive directors to the board, along with representatives on the audit committee and nomination and remuneration committee, subject to specified shareholding thresholds.
The investor will also have consent rights over certain major financial and strategic decisions, including large borrowings, acquisitions, asset disposals and capital expenditure.
These provisions give Advent a degree of oversight over significant corporate decisions while maintaining the investment’s minority-shareholding structure.
The special rights are classified under Regulation 31B of SEBI’s listing regulations and will require public shareholder re-approval every five years.
Why the Investment Is Structured Below 25%
One of the notable aspects of the Yatharth Hospital transaction is the proposed 24.87% stake, which places Advent just below the 25% threshold under SEBI’s takeover regulations.
Under Regulation 3(1), an acquirer reaching 25% or more of a listed company’s voting rights, together with persons acting in concert, is generally required to make an open offer to public shareholders.
A separate open-offer requirement also applies when an acquirer obtains control under Regulation 4.
The transaction’s structure therefore allows Advent to acquire a substantial minority interest without crossing the specified shareholding threshold.
The amended articles also cap the investor’s pre-emption rights on future share issuances at 24.99% and restrict market purchases that could trigger an open offer without promoter consent.
For Yatharth Hospital, the arrangement brings in a large institutional investor while allowing the promoter family to retain its position as the largest shareholder.
Shareholders Back the Capital Infusion, but Governance Rights See Lower Support
The shareholder voting results offer another perspective on the transaction.
The preferential issue received 99.26% overall approval, including 96.5% support from public institutional shareholders.
However, institutional support was lower for some of the accompanying governance arrangements.
The amendment to the articles of association incorporating Advent’s special rights received 56.92% institutional support.
The promoter-rights resolution received 50.55%, while the upside-sharing arrangement for promoter Ajay Kumar Tyagi received 56.39%.
The difference in voting support indicates that shareholders were considerably more aligned on the capital infusion than on some of the additional rights and arrangements associated with the investment.
What Does the Deal Mean for India’s Hospital Investment Landscape?
The Yatharth Hospital transaction brings together three important elements of the healthcare investment ecosystem: expansion capital, institutional ownership and promoter-led hospital businesses.
For Yatharth Hospital, the proposed investment provides a substantial capital base to support its growth plans and strengthen its healthcare network across India.
For Advent International, it creates an opportunity to participate in the expansion of an established multi-speciality hospital chain with operations concentrated in North India.
The transaction was notified to the CCI under Section 5(d) of the Competition Act, 2002, which covers qualifying transactions under the deal-value threshold introduced through the 2023 amendment.
The provision applies to transactions exceeding ₹2,000 crore where the target has substantial business operations in India.
In its submission to the CCI, Rasmalai stated that the investment was intended to support Yatharth Hospital’s expansion as part of Advent‘s focus on India’s healthcare sector.
Yatharth Hospital said the capital would help fund growth and strengthen its healthcare network across India.
With the CCI approval secured, the proposed ₹3,150 crore investment has cleared an important regulatory hurdle. Its completion will depend on the remaining applicable regulatory and statutory requirements.
